Summary "Competitor Landscape: Psoriasis", briefings contain evaluations of ongoing development activities within the psoriasis market, together with analysis of current & potential future product positioning.
Key Highlights from the report - - Certolizumab pegol may find a niche in PsO patients looking to conceive, due to its global approval for use in women of childbearing age - Novartis seeks to identify additional points of differentiation for secukinumab vs. competing biologics by further exploring efficacy and safety in pediatrics and alternative dosing formulations & strategies - BMS-986165 could become the first TYK-2 inhibitor to be approved for PsO, pending positive data from the recently registered Phase III trials
The report comprises five key sections.
Executive Summary: Contains analysis of key market events that have occurred during the previous quarter and which have impacted the Psoriasis landscape.
Landscape Updates - - ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher. - Timeline forecasts for each approved product’s lifecycle management initiatives. - ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies.
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status.
Appendix - Data slides containing the following information - - Current Early Stage Psoriasis Pipeline & candidate ‘Watch List’. - Timeline Assumptions, including standard assumptions & drug specific assumptions.
Scope - The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov) - Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix - Forecasts are presented in pipeline forecast figures & detailed tables - ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy - Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher - Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market - Reviews ongoing lifecycle management strategies for existing players in the market - A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Our reports have been used by over 10K customers, including:
T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019 Summary T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies...
Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2019, provides an overview of the Granulomatosis with Polyangiitis...
C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019 Summary C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)...
Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019 Summary According to the recently published report ’Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019’; Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes...
Uveitis - Pipeline Review, H2 2019 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2019, provides an overview of the Uveitis (Ophthalmology) pipeline landscape. Uveitis is swelling and irritation of the uvea, the middle layer of the eye....
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.